-
Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs
-
Sharp Therapeutics closes fourth tranche of convertible note offering
-
Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering
-
Sharp Therapeutics closes $200,000 convertible note offering
-
Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering
-
Sharp Therapeutics closes second tranche of convertible note offering
-
Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering
-
Sharp Therapeutics closes $500,000 convertible note offering
-
Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering
-
Sharp Therapeutics announces $3 million convertible note offering
-
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
-
Sharp Therapeutics updates private placement to raise at least $10 million
-
Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
-
Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update
-
Sharp Therapeutics arranges $10 million private placement
-
Sharp Therapeutics Arranges Non-Brokered Private Placement
-
Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB

